Top Markets
Coin of the day
Immunotech Laboratories, Inc. Immunotech Laboratories, Inc.

Immunotech Laboratories, Inc.

IMMB
Clasificación en acciones #40594
Immunotech Laboratories, Inc. develops and commercializes proprietary proteins... Immunotech Laboratories, Inc. develops and commercializes proprietary proteins for use in treating human immunodeficiency virus (HIV), acquired immune deficiency syndrome (AIDS), hepatitis, and other immuno-related disorders. Its flagship compound is ITV-1 (immune therapeutic vaccine), a suspension of irreversible pepsin fraction that is used in the treatment of HIV/AIDS and Hepatitis C, as well as to modulate the immune system. The company is headquartered in Monrovia, California. As of June 14, 2017, Immunotech Laboratories, Inc. operates as a subsidiary of Enzolytics, Inc.
Precio por acción
$0.0002
Última sincronización: 2026-08-12
Capitalización bursátil
$114.99K
Cambio (1 día)
0.00%
Cambio (1 año)
100.00%
País
US
Comercio Immunotech Laboratories, Inc. (IMMB)

Categoría

Ganancias de Immunotech Laboratories, Inc. (IMMB)
Ganancias en 2026 TTM: 0
Secondo gli ultimi rapporti finanziari di Immunotech Laboratories, Inc., gli utili attuali della società sono 0. Nel 2026, la società ha registrato un utile di 0, igual a agli utili del 2026, che erano di 0. Gli utili mostrati in questa pagina sono quelli prima degli interessi e delle imposte, ovvero EBIT.
Historial de ganancias de Immunotech Laboratories, Inc. desde 2026 hasta 2026
Ganancias al final de cada año
Año Ganancias Cambiar
Not enough data for the provided dates.
Ganancias de empresas similares o competidoras
Empresa Ganancias Diferencia de ganancias País
$5.27B -
US
$1.95B -
NL
- -
CH
- -
KR
$3.01B -
BE